Producers Online
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with chemotherapy in heavily…
BARCELONA, Spain, Sept. 14, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with…
Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment In a patient with a heavily pretreated leiomyosarcoma, BT-001 was able…
Westford, USA, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the Dietary Supplements Market will attain a value of USD 283 billion by 2031, with a CAGR of 7.4%…
Westford, USA, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that Healthcare Analytics Market will attain the value of USD 212.3 Billion by 2031, with a CAGR of 25.6% during…
FORM 8.3 CORRECTION TO AN OPENING POSITION DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) Amendment – this form…
TORONTO, Sept. 13, 2024 (GLOBE NEWSWIRE) -- (TSX: SBN, SBN.PR.A, PGIC and PGIC.PR.A) Mulvihill Capital Management Inc., the manager of S Split Corp. (“SBN”), announced that, following approval by holders…
Les premières données cliniques présentées à l’ESMO 2024 montrent que BT-001 induit une diminution de la taille des tumeurs chez des patients en échec thérapeutique Chez un patient atteint d’un…
Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically significant segregation of responders in BM+ vs BM-…
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a)…